Skripsi
ADVANCED LUNG CANCER INFLAMMATION INDEX SEBAGAI PREDIKTOR MORTALITAS KANKER PARU STADIUM LANJUT DI RS MOHAMMAD HOESIN PALEMBANG
Background The prognosis of advanced-stage lung cancer remains poor despite ongoing therapeutic advances. Systemic inflammation and nutritional status are increasingly recognized as important prognostic determinants. The Advanced Lung Cancer Inflammation Index (ALI) is a prognostic parameter that evaluates the degree of systemic inflammation by combining body mass index (BMI), serum albumin levels, and the neutrophil-to-lymphocyte ratio (NLR). However, data regarding the association between ALI and mortality in advanced-stage lung cancer patients remain inconsistent. Therefore, this study aimed to evaluate the prognostic value of ALI at Mohammad Hoesin Hospital, Palembang. Methods This was an observational analytic study with a retrospective cohort design conducted at Mohammad Hoesin Hospital, Palembang. Samples were obtained using consecutive sampling from advanced-stage lung cancer patients diagnosed between 2022 and 2024 who met the inclusion criteria. ALI was calculated using baseline patient data. Mortality was assessed through medical records and six-month follow-up. Data analysis was performed using bivariate statistical tests and Kaplan–Meier survival analysis. Results A total of 419 patients with advanced-stage lung cancer were analyzed, with a six-month mortality rate of 53.2%. The median ALI score was significantly lower in the deceased group compared with the surviving group (14.7 vs 25.1; p